Pharmaceutical Lifecycle Management Strategies in 2017

Comprehensive Assessment of Strategies Being Implemented by Pharmaceutical Companies Around the World - Research and Markets

DUBLIN, May 5, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Pharmaceutical Lifecycle Management Strategies in 2017" report to their offering.

Pharmaceutical lifecycle management (LCM) is the process of managing the entire lifecycle of a product including its research, design and manufacture, service and disposal. LCM is a well-established tool to maximize sales throughout the product lifecycle and acts as a competitive edge to provide greater profitability and retain market share as the patent expiry or market exclusivity rights of products approaches. LCM planning will continue to be at the forefront of the pharmaceutical industry's efforts to address declining R&D productivity, stricter reimbursement demands and increasing generic and branded competition.

Companies in the pharmaceutical industry invest significant capital and resources into preserving the patent life and the subsequent profits of products which take several years to produce.

The potential rapid revenue losses that innovator companies in the pharmaceutical industry can experience due to generic competition calls for the incorporation of sophisticated strategies that allow for maximizing a product's lifetime value.

Important challenges include pricing pressures, rising development costs, stringent regulatory and reimbursement policies, declining R&D productivity and drug patent cliffs (the immediate decline in sales after the patent expiration).  These issues, particularly the productivity gap, leave pharmaceutical companies exposed to generic and biosimilar competition, which can erode a significant percentage of their sales and market share within a short period of time. Companies risk losing up to 90% of the revenue of some of their biggest products to generic and biosimilar competition.

The report Pharmaceutical Lifecycle Management Strategies in 2017 provides a comprehensive assessment of product lifecycle (LCM) management strategies that are being implemented by pharmaceutical companies around the world.

In depth, this report enables the following:

- Helps to investigate a wide range of commercial, developmental, legal and regulatory strategies.
- Provides deep analysis into the rationale for implementing LCM strategies, as well as the challenges, risks and commercial opportunities.
- To understand the key challenges that the pharmaceutical industry has been facing in recent years.

Scope

- What is driving the need for effective LCM strategies in the pharmaceutical industry?